ProMIS Neurosciences Q1 net loss $3.6M; cash $2.5M; Phase 1a data on track for mid-2024

ProMIS Neurosciences Inc.

2024-Q1 EPS reported -$0.19

Cash and equivalents $2.5M at March 31, 2024, down from $12.6M at Dec 31, 2023.
Net loss $3.6M in Q1 2024 versus $5.0M in Q1 2023; R&D $2.1M, G&A $1.6M.
Phase 1a PMN310 top-line data expected mid-2024; Phase 1b planned H2 2024 subject to resources.
Neil Warma appointed interim CEO in January 2024, continues as CEO and director.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ProMIS Neurosciences Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.6 million for the quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $3.6 million for the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

Net loss was $3.6 million for the quarter ended March 31, 2024, compared to a net loss of $5.0 million for the same period in 2023.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

ProMIS Neurosciences Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-008140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.